Rodman & Renshaw Initiates Coverage on Omeros (NASDAQ:OMER)

Equities researchers at Rodman & Renshaw initiated coverage on shares of Omeros (NASDAQ:OMER) in a report issued on Thursday, Marketbeat Ratings reports. The brokerage set a “buy” rating and a $9.00 price target on the biopharmaceutical company’s stock. Rodman & Renshaw’s target price would indicate a potential upside of 33.33% from the stock’s previous close.

Separately, StockNews.com downgraded shares of Omeros from a “hold” rating to a “sell” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Omeros presently has an average rating of “Hold” and a consensus price target of $9.00.

Omeros Trading Down 2.9 %

Omeros stock opened at $6.75 on Thursday. Omeros has a 1-year low of $1.38 and a 1-year high of $7.51. The firm has a market capitalization of $391.14 million, a price-to-earnings ratio of -2.92 and a beta of 1.47. The firm has a 50 day simple moving average of $4.08 and a 200 day simple moving average of $4.07.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of OMER. Barclays PLC lifted its holdings in shares of Omeros by 121.3% during the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock worth $376,000 after acquiring an additional 51,873 shares during the last quarter. MML Investors Services LLC lifted its holdings in shares of Omeros by 19.2% during the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 3,000 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Omeros by 15.9% during the 3rd quarter. Jane Street Group LLC now owns 58,277 shares of the biopharmaceutical company’s stock worth $231,000 after acquiring an additional 8,010 shares during the last quarter. Wellington Management Group LLP bought a new stake in shares of Omeros during the 3rd quarter worth $305,000. Finally, State Street Corp lifted its holdings in shares of Omeros by 0.3% during the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after acquiring an additional 3,839 shares during the last quarter. 48.79% of the stock is owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.